Travere Therapeutics (TVTX) Cash & Equivalents: 2013-2025
Historic Cash & Equivalents for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to $110.9 million.
- Travere Therapeutics' Cash & Equivalents rose 204.68% to $110.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $110.9 million, marking a year-over-year increase of 204.68%. This contributed to the annual value of $58.5 million for FY2024, which is 0.62% up from last year.
- Per Travere Therapeutics' latest filing, its Cash & Equivalents stood at $110.9 million for Q3 2025, which was up 47.60% from $75.2 million recorded in Q2 2025.
- In the past 5 years, Travere Therapeutics' Cash & Equivalents registered a high of $256.6 million during Q1 2022, and its lowest value of $32.3 million during Q2 2024.
- In the last 3 years, Travere Therapeutics' Cash & Equivalents had a median value of $61.9 million in 2025 and averaged $77.6 million.
- As far as peak fluctuations go, Travere Therapeutics' Cash & Equivalents tumbled by 74.76% in 2024, and later surged by 204.68% in 2025.
- Travere Therapeutics' Cash & Equivalents (Quarterly) stood at $165.8 million in 2021, then crashed by 62.78% to $61.7 million in 2022, then dropped by 5.69% to $58.2 million in 2023, then climbed by 0.62% to $58.5 million in 2024, then skyrocketed by 204.68% to $110.9 million in 2025.
- Its last three reported values are $110.9 million in Q3 2025, $75.2 million for Q2 2025, and $61.9 million during Q1 2025.